trending Market Intelligence /marketintelligence/en/news-insights/trending/hWfG-vDvoUj-qITl4jwNSA2 content esgSubNav
In This List

Report: BioNTech IPO could fetch up to $800M

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Report: BioNTech IPO could fetch up to $800M

German biopharmaceutical company BioNTech AG has hired banks for a potential IPO that could raise up to $800 million, Reuters reported March 12, citing people familiar with the matter.

BioNTech develops individualized therapies for cancer and other diseases. The company's research platforms involve messenger Ribonucleic acid-based medicines, cell and gene therapies as well as protein therapies. The German company has partnerships with pharmaceutical giants including Roche Holding AG, Eli Lilly and Co., Pfizer Inc. and Sanofi.

Reuters reported that Bank of America and JP Morgan have been hired as global coordinators for the potential Nasdaq IPO.

The IPO could occur in the fourth quarter or early in 2020.

BioNTech, which raised about $270 million in a series A financing led by Redmile Group in January 2018, could be valued at about $4 billion, according to the report.